苯那普利对慢性肾衰合并肾性高血压患者的治疗作用与血浆神经肽Y相关性分析

目的 :探讨慢性肾衰 (CRF)合并肾性高血压患者使用苯那普利治疗前后血压、肾功能、血浆神经肽Y(NPY)含量的变化及其相关性。方法 :CRF合并肾性高血压患者 3 0例 ,使用苯那普利治疗前及用药 4wk后分别测定收缩压 (SBP)、舒张压 (DBP)、血肌酐 (Scr)、血浆NPY ;另采用本院核医学科血浆NPY正常值作对照。结果 :治疗前后血浆NPY水平均高于正常 (P <0 .0 1 )。治疗后与治疗前相比 ,NPY降低明显 (P <0 .0 1 ) ,SBP、DBP及Scr明显下降 (P<0 .0 1 ) ,且血浆NPY与SBP下降有显著相关性 (r=0 .67,P <0 .0 1 )、与DBP、Scr下降关系不明显 (P>0 .0 5 )。结论 :CRF合并肾性高血压患者使用苯那普利治疗后 ,血浆NPY、血压下降 ,肾功能改善

Relationship between effects of benazepril and plasma neuropeptide Y in renal hypertensive patients with chronic renal failure

AIM: To investigate the relationship between the effects of benazepril and plasma neuropeptide Y in renal hypertensive patients with chronic renal failure (CRF). METHODS: The levels of plasma NPY concentration, SBP, DBP and SCr were measured before and after four week treatment with benazepril in thirty renal hypertensive patients. Thirty blood donors from healthy subjects were taken as controls. RESULTS: The plasma NPY concentration was higher in renal hypertensive patients with CRF than in normal controls before and after the treatment. After the treatment, the plasma NPY concentration and SBP, DBP and SCr in renal hypertensive patients were reduced dramatically (P< 0.01 ); NPY showed a remarkable correlation with SBP changes. CONCLUSION: Benazepril can reduce the plasma NPY concentration in renal hypertensive patients with CRF.